Business Wire

Real world evidence demonstrates that risedronate GR (Actonel® GR) has superior outcomes for fracture risk reduction in patients with osteoporosis compared to immediate release oral bisphosphonates

Share

FOR MEDICAL BUSINESS/INDUSTRY TRADE MEDIA ONLY

A real world evidence study, presented at the 13th International Conference on Osteoporosis, Arthritis and Musculoskeletal Disorders has shown for the first time via direct comparison, that risedronate GR (Actonel® GR) demonstrated superior outcomes for fracture risk reduction in patients with osteoporosis, compared to those who received an immediate release (IR) bisphosphonate.1

The study used healthcare claims data from over 5,000 osteoporosis patients to demonstrate a 17% reduction in incidence of any site fractures for patients taking risedronate GR compared with those taking oral IR bisphosphonates (p<0.05).1 This difference was even more pronounced in spine fractures where a 29% reduction in fracture incidence was seen (p<0.05).1 Time to first fracture was delayed for those receiving risedronate GR, reaching statistical significance at 36 months.1 The incidence of gastric adverse events was broadly similar between the two patient groups.1

Lead study investigator, Dr Friederike Thomasius, comments:

“These data are crucial for all healthcare professionals managing osteoporosis and provide an important insight into real-world evidence. I see patients every day who are struggling with medication compliance due to the inflexible regimes of some bisphosphonates. We know that one in three women over the age of 50 will suffer a fragility fracture that can be life changing. As clinicians we need to carefully consider the options for our patients and what this means for lowering fracture risk.”

Bisphosphonates are recommended by guidelines as a first line treatment but there are a number of restrictions associated with how they are taken, for example, the need to fast overnight before taking and for 30 minutes afterwards.2,3,4 Up to a third of patients treated with bisphosphonates take them with food, which may increase fracture risk.5 risedronate GR is the only oral bisphosphonate which can be taken with food due to its enteric coating.6

Robert Stewart, Chief Executive Officer of Theramex, also shared his thoughts:

“We knew that Actonel GR offered a treatment choice that could remove the variability of compliance experienced with oral immediate release bisphosphonates. We set out to explore the impact of this in a real-world setting. What we found was significantly improved clinical outcomes in fracture risk reduction for patients taking Actonel GR versus oral immediate release bisphosphonates. When we consider bisphosphonates are the first line treatment in a condition affecting 200 million women globally, this is an important finding and completely aligned to our mission at Theramex as a company solely dedicated to improving women’s health.”

Ends

Notes to Editor:

About Osteoporosis

Osteoporosis remains largely underdiagnosed and undertreated, resulting in a large number of fractures.

  • It is a significant health issue – affecting ~200 million people worldwide7
  • Osteoporosis affects more women than men and risk increases with age8
  • After the menopause women start to lose bone at a faster rate, raising the risk for women who have had an early menopause or hysterectomy8
  • One in three women aged over 50 will suffer a fragility fracture9
  • Up to a third of patients treated with bisphosphonates (one in three) take their bisphosphonate with food, which may increase fracture risk5
  • Hip, spine and wrist fractures are the most common fractures, which have a debilitating impact on daily activities and quality of life9
  • After a spine fracture mortality decreased over a 5-year period by up to 16% per year10
  • Vertebral fracturescan lead to back pain, loss of height, deformity, immobility, QoL, and activities of daily living11,12,13

About treatment

Bisphosphonates are recommended as first-line treatment for osteoporosis by guidelines. Even when taken correctly, only 1% of the dose is absorbed and this can be impaired by food, calcium, iron, coffee, tea and orange juice.14,15 Most patients take their bisphosphonates before breakfast as there are a number of restrictions when taking oral bisphosphonates, which can be a major inconvenience. Patients must:2,3,4

  • Fast overnight before taking the medication
  • Fast for 30 minutes after taking the medication (before having breakfast)
  • Stay upright for 30 minutes after taking the medication
  • Take with a glass of water (not juice or coffee)
  • Take separately from other medications

Real-world evidence indicates that many patients do not comply with the complex dosing instructions.5 Poor compliance can result in suboptimal efficacy and 45% increased risk of fractures.16

About Risedronate Gastric Resistant (GR) (Actonel®)

Risedronate GR is an oral bisphosphonate which has flexible administration requirements for patients.6 Due to its gastro-resistant enteric coating risedronate GR can bypass the stomach and is absorbed in the small intestine, where the absorption of a bisphosphonate is most important.17 Risedronate GR, therefore,provides 2-4 times higher bioavailability than oral IR bisphosphonates when taken with food.17 Risedronate GR is the only oral bisphosphonate which can be taken with food and, therefore, can be taken immediately after breakfast.6 The flexibility offered by risedronate GR dosing offers a convenient option for patients who may struggle with more restrictive treatment dosing requirements. Risedronate GR was approved by the European Medicines Agency (EMA), as a treatment for patients with Osteoporosis, in October 2016.

About the study1

This retrospective, observational analysis of US healthcare database claims compared the fracture rate and economic burden in female osteoporosis patients who received risedronate GR (n=2,726) with those treated with immediate release bisphosphonates (n=2,726).1 The two cohorts were matched based on patient characteristics and history.1

All patients had ≥1 prescription fill for an oral bisphosphonate, had ≥1 medical claim associated with ≥6 months of continuous eligibility for both pharmacy and medical benefits 6 months prior to the observational period of this study. Patients with a history of Paget’s disease or specific malignancies were excluded from the study.1

Patients without a treatment switch were observed for ≥2 years from the first study-related prescription.1 New fracture events were identified from relevant diagnosis codes from medical claims. In the case of recurrent fracture, the claim was required to occur ≥30 days after the previous fracture claim at distinct skeletal sites and ≥90 days apart if occurring at the same site. Healthcare resource use was also compared.1

About Theramex

For further information on Theramex, please follow this link to the company About Us section of our website: https://www.theramex.com

References:

  1. Thomasius, F. et al. Abstract presented at 13th International Conference on, Osteoporosis, Arthritis and Musculoskeletal Disorders, April 23-24, Dubai 2021
  2. Warner Chilcott UK Ltd. Actonel 5 mg SmPC
  3. Accord Healthcare Ltd. Alendronic acid 10 mg SmPC
  4. Consilient Health Ltd. Ibandronic acid 50 mg SmPC
  5. Vytrisalova et al CLIMACTERIC;18:608–616(2015)
  6. Theramex Ltd. Risedronate sodium gastro-resistant SmPC
  7. Noh JY et al. Int J Mol Sci;21,7623(2020)
  8. IOF. Risk Factors. Last accessed:April 2021
  9. IOF Compendium of Osteoporosis. Last accessed:April 2021
  10. Johnell O et al. Osteoporos Int;15,38-42(2004)
  11. Nevitt MC et al. Ann Intern Med;128:793(1998)
  12. Lips P et al. Osteoporos Int;10:150(1999)
  13. Tosteson AN et al. Osteoporos Int ;2:1042(2001)
  14. Lin J. Bone;18:75–85(1996)
  15. Kanis JA et al. Osteoporosis Int;30:3–44(2019)
  16. Penning-van Beest F.J.A et al. Osteoporos Int;19(4): 511-517(2008)
  17. Pazianas M, et al. Ther Clin Risk Manag;9:395–402(2013)

Job number:ACTOGR_HQ_PRESSR_003521
Date of preparation:April 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Andrew Bradley, Head of Communications Theramex
andrew.bradley@theramex.com +44(0)7864 167962

Helen Rae, Makara Health
helenrae@makarahealth.com +44(0)7503 652311

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kyowa Kirin Provides Update on Application for Marketing Authorisation of Istradefylline in Europe for the Treatment of ‘OFF’ Episodes in People Living with Parkinson’s23.7.2021 16:05:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinson’s, experiencing end-of-dose motor fluctuations. Kyowa Kirin International remain committed to istradefylline and people living with Parkinson’s and are currently reviewing the options available, which may include re-examination. “We are disappointed by the CHMP opinion. However, we remain confident in the benefit-risk profile of istradefylline and are committed to making a difference to the lives of people living with Parkinson’s, an area which has had few innovative therapies for decades,” said Abdul Mullick, President of Kyowa Kirin International. “There are currently few new treatment options available to manage end-of-dose motor fluctuations in Parkinson

ForumPay Teams Up with Bambora to Conquer the Crypto-to-Fiat Payments Market23.7.2021 15:16:00 CEST | Press release

ForumPay, an international cryptocurrency-to-fiat payment service provider, has established a partnership with the global payments provider Bambora, a Worldline brand, to bring seamless crypto payment solutions to merchants and online shoppers. The partnership will cater to a large global audience and offer expanded payment options for both shoppers and merchants. ForumPay continues its march to dominate the growing crypto payments ecosystem for merchants around the world. “ForumPay provides merchants with a seamless, secure and instant processing solution to accept payments from the more than 54 million active crypto wallet users around the world. By providing a payments service for processing crypto into fiat that functions as naturally as card payments, ForumPay enables merchants with a familiar feeling payments alternative that also gives them a competitive advantage by tapping into the fastest growing consumer base on the planet.” says Joshua Tate, CEO of ForumPay. “We are very ex

Wipro Recognized as 2021 Microsoft Modernizing Applications Partner of the Year23.7.2021 14:54:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has won the 2021 Microsoft Partner of the Year Award in the Modernizing Applications category. In addition, Wipro was also named as a category finalist in the 2021 AI Partner of the Year category, solidifying its reputation as an innovator in multiple sectors. This recognition highlights Wipro’s deep expertise and ability to go above and beyond for its customers, powered by an established partnership with Microsoft. Even when working with complex customer environments, spanning across hundreds of servers with different applications of different versions, Wipro was able to help customers meet their business needs and leverage the power of public cloud in an efficient way. “Global enterprises have embraced modernization at an unprecedented scale and pace, and the demands of the past year show no sign of easing. We are honor

Merck Announces Appointment of Head of China & International for Healthcare23.7.2021 13:45:00 CEST | Press release

Merck, a leading science and technology company, today announced that Hong Chow will join its Healthcare business sector as Head of China & International on October 1. In this role at Merck, Chow will lead China, Japan as well the regions Europe, Latin America, Asia-Pacific and Middle East, Africa and Russia, the franchise of Cardiovascular Metabolism & Endocrinology (CM&E), and the Global Business Innovation team. Chow will report to Peter Guenter, Member of the Executive Board of Merck and CEO Healthcare. She will serve as a member of the Healthcare Executive Committee, and be based in Shanghai, China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210723005186/en/ Merck Announces Appointment of Head of China & International for Healthcare (Photo: Business Wire) “Hong’s international experience and strong track record of bringing innovative medicines to patients in need across both developed and emerging markets, most nota

H.I.G. WhiteHorse Refinances Grupo Recoletas23.7.2021 13:03:00 CEST | Press release

H.I.G. WhiteHorse, a credit affiliate of global investment firm H.I.G. Capital ("H.I.G.") is pleased to announce that it has arranged a refinancing package for Grupo Hospitalario Recoletas (“Recoletas”), which includes a significant growth capital component. Recoletas is a family-owned Spanish private hospital operator headquartered in Valladolid, Spain, with a leading position in the Castilla y Leon Spanish inland region. It operates 8 hospitals with c. 540 beds and 13 medical centres across 7 regions. H.I.G. WhiteHorse has committed €110 million in unitranche loans to refinance the borrower's existing indebtedness and provide additional capital to finance growth, supporting the Company’s expansion. Recoletas is currently developing ambitious projects to expand its healthcare services provided through hospitals and medical centers, as well as diagnostic imaging centers and radiotherapy units. Amando J. Rodríguez, President and CEO of Grupo Hospitalario Recoletas, said: “We are very ha

Schlumberger Announces Second-Quarter 2021 Results23.7.2021 12:50:00 CEST | Press release

Schlumberger Limited (NYSE: SLB) today reported results for the second-quarter 2021. Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2021Mar. 31, 2021Jun. 30, 2020SequentialYear-on-yearRevenue* $5,634 $5,223 $5,356 8% 5% Income (loss) before taxes - GAAP basis $542 $386 $(3,627) 40% n/m Net income (loss) - GAAP basis $431 $299 $(3,434) 44% n/m Diluted EPS (loss per share) - GAAP basis $0.30 $0.21 $(2.47) 43% n/m Adjusted EBITDA** $1,198 $1,049 $838 14% 43% Adjusted EBITDA margin** 21.3% 20.1% 15.6% 118 bps 561 bps Pretax segment operating income** $807 $664 $396 22% 104% Pretax segment operating margin** 14.3% 12.7% 7.4% 162 bps 694 bps Net income, excluding charges & credits** $431 $299 $69 44% 525% Diluted EPS, excluding charges & credits** $0.30 $0.21 $0.05 43% 500% Revenue by Geography International $4,511 $4,211 $4,224 7% 7% North America* 1,083 972 1,097 11% -1% Other 40 40 35 n/m n/m $5,634 $5,223 $5,356 8% 5% *Schlumberger di

Wyss Center Partners With Artiria Medical to Accelerate a Novel Therapy for Cerebral Vasospasm23.7.2021 11:59:00 CEST | Press release

The Wyss Center and Artiria Medical today announced a new partnership to accelerate the translation of a novel technology that has the potential to reduce deaths and improve quality of life for stroke patients. Artiria Medical, an early-stage medical device company focused on disruptive neurovascular products, has been developing the technology and is now joining forces with the Wyss Center, a non-profit organization dedicated to bringing state-of-the-art therapies to the patient. The team has received support from the Swiss Innovation Agency, Innosuisse, to test and validate the efficacy of the therapy preclinically, in preparation for human clinical studies. Stroke is the third leading cause of disability worldwide with more than 80 million people living with long-term impairments as a result. Some strokes result in bleeding in the brain. Such hemorrhagic strokes can lead to severe cerebral vasospasm - an uncontrolled contraction of brain arteries - in the days that follow, depriving

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom